Protalix BioTherapeutics, Inc. has completed a private stock placement
March 2020 — Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Our role in the transaction
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Talk to the deal team
Related deals
Heka Dental has joined forces with Impilo to anchor focused buy-and-build strategy
Heka Dental, a leading Danish designer and manufacturer of premium dental treatment units, has been acquired by the Swedish private equity firm Impilo. The acquisition establishes Heka Dental as a strategic platform for consolidation in the European dental equipment market. Impilo will execute a focused buy-and-build strategy to accelerate growth and expand its footprint across Europe.
Learn moreitemedical has been acquired by Halma
itemedical, a Netherlands-based provider of digital platforms that integrate real-time patient data and alarms from a wide range of medical devices to support clinical decision-making and workflow efficiency in hospitals, has been acquired by Halma plc, a global group of life-saving technology companies. The acquisition represents a milestone in itemedical’s development and provides a platform for its next phase of growth. By joining Halma’s healthcare sector as a business unit of Halma subsidiary Static Systems Group (SSG), itemedical will strengthen its position as a provider of digital hospital workflow solutions, benefiting from access to a global network of technology businesses, resources to accelerate innovation and opportunities to expand its international footprint.
Learn moreBoeser Frischfleisch has secured financing for the acquisition of Vion Crailsheim
Boeser Frischfleisch GmbH has secured financing in connection with the acquisition of the Crailsheim site from Vion Group. The site specializes in the slaughtering and cutting of cattle and pigs and plays an important role in the southern German meat industry. Through the acquisition, Boeser Frischfleisch expands its value chain and strengthens its position in a market characterized by ongoing structural change and consolidation.
Learn more